Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. (Record no. 20504797)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02330 a2200637 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250516020820.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201110s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1557-3265 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1158/1078-0432.CCR-10-2345 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Shapiro, Geoffrey I |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20111007 |
| 245 00 - TITLE STATEMENT | |
| Title | Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Date of publication, distribution, etc. | May 2011 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 3431-42 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Adult |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aged, 80 and over |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | adverse effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cisplatin |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease Progression |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Female |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | G2 Phase |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Genes, cdc |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Male |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Maximum Tolerated Dose |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Middle Aged |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Peptide Fragments |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | cdc25 Phosphatases |
| General subdivision | administration & dosage |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tibes, Raoul |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gordon, Michael S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wong, Bryan Y |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Eder, Joseph Paul |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Borad, Mitesh J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mendelson, David S |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Vogelzang, Nicholas J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bastos, Bruno R |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Weiss, Glen J |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fernandez, Cristian |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sutherland, William |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sato, Hitoshi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Pierceall, William E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Weaver, David |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Slough, Scott |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wasserman, Ernesto |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kufe, Donald W |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Von Hoff, Daniel |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kawabe, Takumi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Sharma, Sunil |
| 773 0# - HOST ITEM ENTRY | |
| Title | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Related parts | vol. 17 |
| -- | no. 10 |
| -- | p. 3431-42 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1158/1078-0432.CCR-10-2345">https://doi.org/10.1158/1078-0432.CCR-10-2345</a> |
| Public note | Available from publisher's website |
No items available.